1W Return
1M Return
6M Return
1Y Return
3Y Return
Open
Prev. Close
Total Traded Value
Market Cap (in crs)
Face Value
Turnover (in lacs)
*All values are in ₹ Cr.
*All values are in ₹ Cr.
*All values are in ₹ Cr.
*All values are in ₹ Cr.
Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
---|---|---|---|---|
641.92 Cr | 590.62 Cr | 560.01 Cr | 586.13 Cr | 531.24 Cr |
Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
---|---|---|---|---|
2227.83 Cr | 1911.45 Cr | 1532.69 Cr | 1382.88 Cr | 1134.54 Cr |
Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
---|---|---|---|---|
97.76 Cr | 89.07 Cr | 77.64 Cr | 82.96 Cr | 83.85 Cr |
Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
---|---|---|---|---|
314.9 Cr | 265.32 Cr | 186.81 Cr | 238.54 Cr | 120.75 Cr |
Period | Combined Delivery Volume | NSE+BSE Traded Volume |
---|---|---|
Day Rs | 704768 Rs | 2088216 Rs |
Week Rs | 722172 Rs | 1873153 Rs |
Month Rs | 967726 Rs | 3683730 Rs |
Company | Market Price | Market Cap | 52W Low | 52W High |
---|---|---|---|---|
16545 | 4600.7 | 8139 | ||
18772.23 | 1178 | 2490 | ||
14185.84 | 365.45 | 721 | ||
18309.94 | 452.8 | 1309.9 | ||
14264.67 | 5892.8 | 10524.95 | ||
14138.4 | 470.1 | 736.3 |
Marksans Pharma Ltd shares are currently priced at 322.75 on NSE and 322.75 on BSE as of 12/10/2024 12:00:00 AM. Please be aware that stock prices are subject to continuous fluctuations due to various factors.
The past 1-year return of Marksans Pharma Ltd [MARKSANS] share was 97.82. The Marksans Pharma Ltd [MARKSANS] share hit a 1-year low of Rs. 130 and a 1-year high of Rs. 358.7.
The market cap of Marksans Pharma Ltd is Rs. 14625.86 Cr. as of 12/10/2024 12:00:00 AM.
The PE ratios of Marksans Pharma Ltd is 95.21 as of 12/10/2024 12:00:00 AM.
The PB ratios of Marksans Pharma Ltd is 11.33 as of 12/10/2024 12:00:00 AM
The Mutual Fund Shareholding was 3.02% at the end of 12/10/2024 12:00:00 AM.
You can easily buy Marksans Pharma Ltd shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.